Lung Cancer Clinical Trial

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Summary

The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).

Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR.

Hypothesis (H2): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR.

Hypothesis (H3): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to OS.

Hypothesis (H4): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to OS.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has pathologically (histologically or cytologically) confirmed Small Cell Lung Cancer (SCLC).

Note: Note: Participants with histology showing a mixed tumor with small cell and non-small cell elements are not eligible.

Has Limited-Stage SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses.
Has no evidence of metastatic disease by whole body positron emission tomography /computed tomography (PET/CT scan), CT or magnetic resonance imaging (MRI) scans
Has at least 1 lesion that meets the criteria for being measurable, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Has not received prior treatment (chemotherapy or radiotherapy or surgery resection) of LS-SCLC.
Is not expected to require tumor resection during the course of the study.
Must submit a pre-treatment tumor tissue sample (formalin-fixed, paraffin embedded blocks are preferred to slides) including cytologic sample, if tissue sample unavailable.
Has Eastern Cooperative Oncology Group (ECOG) Performance score 0 or 1 assessed within 7 days prior to the first administration of study intervention.
Has a life expectancy of at least 6 months.
Has adequate organ function.
Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for the time needed to eliminate each study intervention.
Male and female participants who are at least 18 years of age at the time of signing the information consent.
Male participants must refrain from donating sperm during the treatment period and for the time needed to eliminate each study intervention.

Abstains from breastfeeding during the study intervention period and for at least the following period after the last study intervention:

Pembrolizumab: 120 days
Olaparib: 7 days

Exclusion Criteria:

Has history, current diagnosis, or features suggestive of myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML).
Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PDL1), or anti- programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
Has received prior therapy with olaparib or with any other polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
Had major surgery <4 weeks prior to the first dose of study intervention (except for placement vascular access).
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.
Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
Has severe hypersensitivity (≥ Grade 3) to study intervention and/or any of its excipients.
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a history of (non-infectious) pneumonitis/interstitial lung disease that requires steroids
Has an active infection requiring systemic therapy.
Has a known history of human immunodeficiency virus (HIV) infection or Hepatitis B or known active Hepatitis C virus infection.

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

672

Study ID:

NCT04624204

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 164 Locations for this study

See Locations Near You

Ironwood Cancer & Research Centers ( Site 0007)
Chandler Arizona, 85224, United States More Info
Study Coordinator
Contact
480-398-7674
Loma Linda University Cancer Center ( Site 0011)
Loma Linda California, 92350, United States More Info
Study Coordinator
Contact
909-558-4050
Georgetown University ( Site 0017)
Washington District of Columbia, 20007, United States
Fort Wayne Medical Oncology and Hematology ( Site 0034)
Fort Wayne Indiana, 46804, United States More Info
Study Coordinator
Contact
260-436-0800
Overton Brooks VAMC ( Site 0041)
Shreveport Louisiana, 71101, United States
Harry & Jeanette Weinberg Cancer Institute ( Site 0045)
Baltimore Maryland, 21237, United States More Info
Study Coordinator
Contact
443-777-7364
VA Ann Arbor Healthcare System ( Site 0050)
Ann Arbor Michigan, 48105, United States More Info
Study Coordinator
Contact
734-769-7100
St. Vincent Healthcare Frontier Cancer Center ( Site 0056)
Billings Montana, 59102, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061)
Omaha Nebraska, 68130, United States More Info
Study Coordinator
Contact
308-398-5450
Memorial Sloan Kettering - Basking Ridge ( Site 0133)
Basking Ridge New Jersey, 07920, United States More Info
Study Coordinator
Contact
646-608-3793
John Theurer Cancer Center ( Site 0064)
Hackensack New Jersey, 07601, United States
Memorial Sloan Kettering - Monmouth ( Site 0135)
Middletown New Jersey, 07748, United States More Info
Study Coordinator
Contact
848-225-6000
Memorial Sloan Kettering - Bergen ( Site 0130)
Montvale New Jersey, 07645, United States More Info
Study Coordinator
Contact
646-608-3793
Rutgers Cancer Institute of New Jersey ( Site 0123)
New Brunswick New Jersey, 08903, United States More Info
Study Coordinator
Contact
732-235-2465
Memorial Sloan Kettering- Commack ( Site 0132)
Commack New York, 11725, United States More Info
Study Coordinator
Contact
646-608-3793
Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134)
Harrison New York, 10604, United States More Info
Study Coordinator
Contact
646-608-3793
Memorial Sloan Kettering Cancer Center ( Site 0069)
New York New York, 10021, United States More Info
Study Coordinator
Contact
646-608-3793
Memorial Sloan Kettering - Nassau ( Site 0131)
Uniondale New York, 11553, United States More Info
Study Coordinator
Contact
646-608-3793
Penn State Hershey Cancer Institute ( Site 0081)
Hershey Pennsylvania, 17033, United States More Info
Study Coordinator
Contact
717-531-8521
Saint Francis Cancer Center ( Site 0087)
Greenville South Carolina, 29607, United States More Info
Study Coordinator
Contact
864-603-6200
The University of Tennessee Medical Center ( Site 0116)
Knoxville Tennessee, 37920, United States More Info
Study Coordinator
Contact
865-305-4893
Texas Oncology - Dallas (Presbyterian)_McIntyre ( Site 0098)
Dallas Texas, 75231, United States More Info
Study Coordinator
Contact
214-739-4175
Texas Oncology - Dallas (Sammons) ( Site 0093)
Dallas Texas, 75246, United States More Info
Study Coordinator
Contact
214-826-9797
MD Anderson Cancer Center ( Site 0100)
Houston Texas, 77030, United States More Info
Study Coordinator
Contact
844-215-4940
Providence Regional Cancer Partnership ( Site 0106)
Everett Washington, 98201, United States More Info
Study Coordinator
Contact
425-297-5577
Multicare Institute For Research And Innovation ( Site 0108)
Tacoma Washington, 98405, United States More Info
Study Coordinator
Contact
253-403-3321
Virginia Mason Memorial- North Star Lodge Cancer Center ( Site 0112)
Yakima Washington, 98902, United States More Info
Study Coordinator
Contact
509-574-3400
Campbelltown Hospital ( Site 3002)
Campbelltown New South Wales, 2560, Australia More Info
Study Coordinator
Contact
+61246344300
Nepean Hospital ( Site 3001)
Kingswood New South Wales, 2747, Australia More Info
Study Coordinator
Contact
+61247343500
Calvary Mater Newcastle ( Site 3000)
Waratah New South Wales, 2298, Australia More Info
Study Coordinator
Contact
+61240143282
Gold Coast University Hospital ( Site 3003)
Southport Queensland, 4215, Australia More Info
Study Coordinator
Contact
+61756870000
Frankston Hospital-Oncology and Haematology ( Site 3007)
Frankston Victoria, 3199, Australia More Info
Study Coordinator
Contact
+61397847175
Austin Health-Austin Hospital ( Site 3006)
Heidelberg Victoria, 3084, Australia More Info
Study Coordinator
Contact
+61394969863
Western Health-Sunshine Hospital ( Site 3004)
St Albans Victoria, 3021, Australia More Info
Study Coordinator
Contact
+61385959167
Saint-Luc UCL ( Site 1005)
Brussels Bruxelles-Capitale, Region De, 1200, Belgium More Info
Study Coordinator
Contact
+3227642833
Grand Hopital de Charleroi ( Site 1003)
Charleroi Hainaut, 6000, Belgium More Info
Study Coordinator
Contact
+3271104766
C.I.U. Hopital Ambroise Pare ( Site 1001)
Mons Hainaut, 7000, Belgium More Info
Study Coordinator
Contact
+3265413746
CHU UCL Namur Site de Godinne ( Site 1004)
Yvoir Namur, 5530, Belgium More Info
Study Coordinator
Contact
+3281422111
UZ Leuven ( Site 1002)
Leuven Vlaams-Brabant, 3000, Belgium More Info
Study Coordinator
Contact
+3216346802
AZ Delta ( Site 1000)
Roeselare West-Vlaanderen, 8800, Belgium More Info
Study Coordinator
Contact
+3251237216
MHAT "Uni Hospital" OOD ( Site 2507)
Panagyurishte Pazardzhik, 4500, Bulgaria More Info
Study Coordinator
Contact
00359885797096
Cross Cancer Institute ( Site 0206)
Edmonton Alberta, T6G 1, Canada More Info
Study Coordinator
Contact
7804328762
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0202)
Montreal Quebec, H3T 1, Canada More Info
Study Coordinator
Contact
5143453511 x6734
McGill University Health Centre ( Site 0210)
Montréal Quebec, H4A 3, Canada More Info
Study Coordinator
Contact
5149341934 ext38930
CIUSSS de la Mauricie et du Centre du Quebec ( Site 0200)
Trois-Rivieres Quebec, G8Z 3, Canada More Info
Study Coordinator
Contact
8196973333
Peking Union Medical College Hospital ( Site 3102)
Beijing Beijing, 10000, China More Info
Study Coordinator
Contact
+86 10 69156114
Cancer Hospital Chinese Academy of Medical Sciences ( Site 3104)
Beijing Beijing, 10002, China More Info
Study Coordinator
Contact
+8613520445135
Beijing Cancer Hospital ( Site 3127)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
13701224460
Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 3140)
Beijing Beijing, 10014, China
Chongqing Cancer Hospital ( Site 3135)
Chongqing Chongqing, 40003, China More Info
Study Coordinator
Contact
02365456552
Daping Hospital,Third Military Medical University ( Site 3136)
Chongqing Chongqing, 40004, China
Fujian Provincial Cancer Hospital ( Site 3126)
Fuzhou Fujian, 35001, China More Info
Study Coordinator
Contact
+8613906900190
The First Affiliated Hospital of Xiamen University ( Site 3121)
Xiamen Fujian, 36100, China More Info
Study Coordinator
Contact
8613806000926
Peking University Shenzhen Hospital ( Site 3118)
Shenzhen Guangdong, 51803, China More Info
Study Coordinator
Contact
+8613823394076
Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3113)
Shenzhen Guangdong, 51811, China More Info
Study Coordinator
Contact
0755-66619602
Henan Cancer Hospital ( Site 3105)
Zhengzhou Henan, 45000, China More Info
Study Coordinator
Contact
865512922342
Wuhan Union Hospital ( Site 3123)
Wuhan Hubei, 43002, China
Tongji Medical College Huazhong University of Science and Technology ( Site 3138)
Wuhan Hubei, 43003, China More Info
Study Coordinator
Contact
+8613006179858
Hubei Cancer Hospital ( Site 3120)
Wuhan Hubei, 43007, China More Info
Study Coordinator
Contact
027-87670138
Hunan Cancer Hospital ( Site 3133)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
8613973135460
Xiangya Hospital of Central South University ( Site 3137)
Changsha Hunan, 41000, China
Second Xiangya Hospital of Central-South University ( Site 3128)
Changsha Hunan, 41001, China More Info
Study Coordinator
Contact
0731-85292097
Jiangsu Cancer Hospital ( Site 3139)
Nanjing Jiangsu, 21000, China More Info
Study Coordinator
Contact
+8613913909043
The Second Affiliated Hospital of Nanchang University ( Site 3106)
Nanchang Jiangxi, 33000, China More Info
Study Coordinator
Contact
8613767120022
The First Hospital of Jilin University ( Site 3132)
Changchun Jilin, 13002, China More Info
Study Coordinator
Contact
+86043188783373
Shandong Province Cancer Hospital ( Site 3100)
Jinan Shandong, 25011, China More Info
Study Coordinator
Contact
0531-67627107
Shanghai Chest Hospital ( Site 3107)
Shangai Shanghai, 20003, China More Info
Study Coordinator
Contact
021-22200000
Shanghai Pulmonary Hospital ( Site 3101)
Shanghai Shanghai, 20044, China More Info
Study Coordinator
Contact
02165115006
West China Hospital of Sichuan University ( Site 3114)
Chengdu Sichuan, 51011, China
Tianjin Medical University Cancer Institute & Hospital ( Site 3103)
Tianjin Tianjin, 30006, China More Info
Study Coordinator
Contact
+8613102258620
Hangzhou Cancer Hospital ( Site 3129)
Hanghzou Zhejiang, 31000, China More Info
Study Coordinator
Contact
18857110928
The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3131)
Hangzhou Zhejiang, 31000, China More Info
Study Coordinator
Contact
+8613957162839
Zhejiang Cancer Hospital.... ( Site 3108)
Hangzhou Zhejiang, 31002, China More Info
Study Coordinator
Contact
0571-88122261
SA Pohja-Eesti Regionaalhaigla ( Site 2201)
Tallinn Harjumaa, 13419, Estonia More Info
Study Coordinator
Contact
+3725222273
SA Tartu Ulikooli Kliinikum ( Site 2200)
Tartu Tartumaa, 51014, Estonia More Info
Study Coordinator
Contact
+3735513443
C.H. de Saint Quentin ( Site 1111)
Saint Quentin Aisne, 02321, France More Info
Study Coordinator
Contact
+33360125235
Clinique Clairval ( Site 1108)
Marseille Bouches-du-Rhone, 13009, France More Info
Study Coordinator
Contact
0033496196230
CHU Grenoble -Hop Michallon ( Site 1102)
Grenoble Isere, 38043, France More Info
Study Coordinator
Contact
+33476767575
Institut De Cancerologie De L Ouest ( Site 1110)
Saint Herblain Loire-Atlantique, 44805, France More Info
Study Coordinator
Contact
+33240679821
Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1103)
Angers Maine-et-Loire, 49000, France More Info
Study Coordinator
Contact
+33241352739
Hopital Avicenne ( Site 1106)
Bobigny Seine-Saint-Denis, 93000, France
H.I.A. Sainte-Anne ( Site 1101)
Toulon Var, 83800, France More Info
Study Coordinator
Contact
+33483162916
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1105)
Paris , 75014, France More Info
Study Coordinator
Contact
+33158413091
Henry Dunant Hospital ( Site 1205)
Athens Attiki, 115 2, Greece More Info
Study Coordinator
Contact
+306983519989
Sotiria Regional Chest Diseases Hospital of Athens ( Site 1200)
Athens Attiki, 115 2, Greece More Info
Study Coordinator
Contact
+302107700220
University General Hospital of Herakleion ( Site 1202)
Heraklion Irakleio, 711 1, Greece More Info
Study Coordinator
Contact
302810392750
Anti-Cancer Hospital of Thessaloniki Theagenio ( Site 1204)
Thessaloniki Kentriki Makedonia, 54007, Greece More Info
Study Coordinator
Contact
+302310898721
University General Hospital of Larisa ( Site 1201)
Larissa Thessalia, 411 1, Greece More Info
Study Coordinator
Contact
+302413502027
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1306)
Kecskemét Bacs-Kiskun, 6000, Hungary More Info
Study Coordinator
Contact
003676519853
Petz Aladar Megyei Oktato Korhaz ( Site 1312)
Gyor Gyor-Moson-Sopron, 9024, Hungary More Info
Study Coordinator
Contact
+3696507900
Tudogyogyintezet Torokbalint ( Site 1304)
Torokbalint Pest, 2045, Hungary More Info
Study Coordinator
Contact
+3623511570
Orszagos Koranyi Pulmonologiai Intezet ( Site 1301)
Budapest , 1121, Hungary More Info
Study Coordinator
Contact
0036205651900
Orszagos Onkologiai Intezet ( Site 1310)
Budapest , 1122, Hungary More Info
Study Coordinator
Contact
+3612248600
Uzsoki Utcai Korhaz ( Site 1303)
Budapest , 1145, Hungary More Info
Study Coordinator
Contact
+3614673700/1061
Rambam Health Care Campus-Oncology Division ( Site 1401)
Haifa , 31096, Israel More Info
Study Coordinator
Contact
+97247776700
Chaim Sheba Medical Center ( Site 1400)
Ramat Gan , 52620, Israel More Info
Study Coordinator
Contact
+97235307096
A O U Policlinico di Modena ( Site 1503)
Modena Emilia-Romagna, , Italy More Info
Study Coordinator
Contact
+39 3381446063
Azienda Ospedaliero Universitaria Careggi ( Site 1509)
Florence Firenze, 50134, Italy More Info
Study Coordinator
Contact
+393209225506
IRCCS Ospedale San Raffaele ( Site 1500)
Milano , 20132, Italy More Info
Study Coordinator
Contact
390226436627
Istituto Nazionale dei Tumori ( Site 1504)
Milano , 20133, Italy More Info
Study Coordinator
Contact
+390223903813
Istituto Europeo di Oncologia ( Site 1501)
Milano , 20141, Italy More Info
Study Coordinator
Contact
+390257489440
IRCCS Istituto Oncologico Veneto ( Site 1506)
Padova , 35128, Italy More Info
Study Coordinator
Contact
+39 3923633461
Policlinico Universitario Agostino Gemelli ( Site 1505)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390630155202
Aichi Cancer Center Hospital ( Site 4010)
Nagoya Aichi, 464-8, Japan More Info
Study Coordinator
Contact
+81-52-762-6111
Kobe Minimally Invasive Cancer Center ( Site 4003)
Kobe Hyogo, 650-0, Japan More Info
Study Coordinator
Contact
+81-78-304-4100
Takarazuka City Hospital ( Site 4013)
Takarazuka Hyogo, 665-0, Japan More Info
Study Coordinator
Contact
+81-797-87-1161
Kanagawa Cancer Center ( Site 4001)
Yokohama Kanagawa, 241-8, Japan More Info
Study Coordinator
Contact
+81-45-520-2222
Kansai Medical University Hospital ( Site 4009)
Hirakata Osaka, 573-1, Japan More Info
Study Coordinator
Contact
+81-72-804-0101
Osaka Medical and Pharmaceutical University Hospital ( Site 4007)
Takatsuki Osaka, 569-8, Japan More Info
Study Coordinator
Contact
+81-72-683-1221
Shizuoka Cancer Center ( Site 4014)
Nagaizumi Shizuoka, 411-8, Japan More Info
Study Coordinator
Contact
+81559895222
National Hospital Organization Kyushu Cancer Center ( Site 4000)
Fukuoka , 811-1, Japan More Info
Study Coordinator
Contact
+81-92-541-3231
Niigata Cancer Center Hospital ( Site 4004)
Niigata , 951-8, Japan More Info
Study Coordinator
Contact
+81-25-266-5111
Okayama University Hospital ( Site 4012)
Okayama , 70085, Japan More Info
Study Coordinator
Contact
+81-86-223-7151
Osaka International Cancer Institute ( Site 4005)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81-6-6945-1181
National Cancer Center Hospital ( Site 4015)
Tokyo , 104-0, Japan More Info
Study Coordinator
Contact
+81-3-3542-2511
Juntendo University Hospital ( Site 4008)
Tokyo , 113-0, Japan More Info
Study Coordinator
Contact
+81-3-3813-3111
Tokyo Metropolitan Komagome Hospital ( Site 4011)
Tokyo , 113-8, Japan More Info
Study Coordinator
Contact
+81-3-3823-2101
The Cancer Institute Hospital of JFCR ( Site 4006)
Tokyo , 135-8, Japan More Info
Study Coordinator
Contact
+81-3-3520-0111
Showa University Hospital ( Site 4002)
Tokyo , 142-8, Japan More Info
Study Coordinator
Contact
+81-3-3784-8000
National Cancer Center ( Site 3306)
Goyang-si Kyonggi-do, 10408, Korea, Republic of More Info
Study Coordinator
Contact
+82319201694
The Catholic University of Korea St. Vincent s Hospital ( Site 3303)
Gyeonggi-do Kyonggi-do, 16247, Korea, Republic of More Info
Study Coordinator
Contact
+82312498153
Seoul National University Bundang Hospital ( Site 3301)
Seongnam-si Kyonggi-do, 13620, Korea, Republic of More Info
Study Coordinator
Contact
+82317877003
Inje University Haeundae Paik Hospital ( Site 3307)
Busan Pusan-Kwangyokshi, 48108, Korea, Republic of More Info
Study Coordinator
Contact
+82517970008
Asan Medical Center ( Site 3308)
Songpagu Seoul, 05505, Korea, Republic of More Info
Study Coordinator
Contact
+82230105935
Keimyung University Dongsan Hospital ( Site 3302)
Daegu Taegu-Kwangyokshi, 42601, Korea, Republic of More Info
Study Coordinator
Contact
+82532587716
Severance Hospital Yonsei University Health System ( Site 3304)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82222288126
Samsung Medical Center ( Site 3300)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
+82234101795
Nacionalinis Vezio Institutas ( Site 2300)
Vilnius Vilniaus Miestas, 08406, Lithuania More Info
Study Coordinator
Contact
+37052786748
LSMUL Kauno Klinikos ( Site 2301)
Kaunas , 50161, Lithuania More Info
Study Coordinator
Contact
+37037326457
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0401)
Guadalajara Jalisco, 44280, Mexico More Info
Study Coordinator
Contact
523315145351
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 0404)
Monterrey Nuevo Leon, 64460, Mexico More Info
Study Coordinator
Contact
+528183338111
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 1705)
Lisboa , 1099-, Portugal More Info
Study Coordinator
Contact
+351217229800
Amethyst Radiotherapy Center-Oncologie Medicala ( Site 2805)
Florești Cluj, 40728, Romania More Info
Study Coordinator
Contact
+40742206212
Spitalul Municipal Ploiesti ( Site 2801)
Ploiesti Prahova, 10033, Romania More Info
Study Coordinator
Contact
+40740062630
Cabinet Medical Oncomed ( Site 2802)
Timisoara Timis, 30023, Romania More Info
Study Coordinator
Contact
+40256495403
S.C.Focus Lab Plus S.R.L ( Site 2804)
Bucuresti , 02254, Romania More Info
Study Coordinator
Contact
+40721298677
Moscow Regional Oncological Dispensary-Oncology (thoracic surgery) Department №1 ( Site 1815)
Balashikha Moskovskaya Oblast, 14390, Russian Federation
Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 1812)
Moscow Moskva, 10509, Russian Federation
MROI n.a. P.A. Herzen - branch of FSBI NMICR of MoH of Russia ( Site 1800)
Moscow Moskva, 12528, Russian Federation
Nizhniy Novgorod Region Oncology Dispensary ( Site 1811)
Nizhny Novgorod Nizhegorodskaya Oblast, 60308, Russian Federation
Omsk Clinical Oncology Dispensary ( Site 1806)
Omsk Omskaya Oblast, 64401, Russian Federation
Sverdlovsk Regional Oncology Hospital ( Site 1807)
Ekaterinburg Sverdlovskaya Oblast, 62003, Russian Federation
Republican Clinical Oncology Dispensary-Chemotherapy #1 ( Site 1814)
Kazan Tatarstan, Respublika, 42002, Russian Federation
Institut za plucne bolesti Vojvodine Sremska Kamenica ( Site 2991)
Sremska Kamenica Sremski Okrug, 21204, Serbia More Info
Study Coordinator
Contact
381642636187
Steve Biko Academic Hospital ( Site 5000)
Pretoria Gauteng, 0002, South Africa More Info
Study Coordinator
Contact
+27123466701
Groote Schuur Hospital ( Site 5002)
Cape Town Western Cape, 7925, South Africa More Info
Study Coordinator
Contact
+27214044266
Hospital Universitario Central de Asturias ( Site 1900)
Oviedo Asturias, 33011, Spain More Info
Study Coordinator
Contact
34985106100x39705
Hospital Duran i Reynals ( Site 1903)
Hospitalet de Llobregat Barcelona, 08908, Spain More Info
Study Coordinator
Contact
+34932607744
Hospital Universitari Vall d Hebron ( Site 1904)
Barcelona , 08035, Spain More Info
Study Coordinator
Contact
+34934894158
Hospital Universitario 12 de Octubre ( Site 1902)
Madrid , 28041, Spain More Info
Study Coordinator
Contact
+34914692313
Hospital Regional Universitario de Malaga ( Site 1905)
Malaga , 29010, Spain More Info
Study Coordinator
Contact
+34951291425
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1907)
Sevilla , 41009, Spain More Info
Study Coordinator
Contact
+34955926578
Ankara Sehir Hastanesi ( Site 2007)
Ankara , 06800, Turkey More Info
Study Coordinator
Contact
+905555306271
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2009)
Istanbul , 34098, Turkey More Info
Study Coordinator
Contact
+905324167355
Medipol Universite Hastanesi ( Site 2005)
Istanbul , 34214, Turkey More Info
Study Coordinator
Contact
+905325280486
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2003)
Istanbul , 34722, Turkey More Info
Study Coordinator
Contact
+905063509061
Ege Universitesi Tip Fakultesi Hastanesi ( Site 2001)
Izmir , 35040, Turkey More Info
Study Coordinator
Contact
+905322202675
Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107)
Dnipro Dnipropetrovska Oblast, 49055, Ukraine
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2110)
Kharkiv Kharkivska Oblast, 61024, Ukraine
Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104)
Kapitanivka Village Kyivska Oblast, 08111, Ukraine
Clinic of National Cancer Institute ( Site 2101)
Kyiv Kyivska Oblast, 03022, Ukraine
Medical Center Verum ( Site 2106)
Kyiv Kyivska Oblast, 03039, Ukraine
LISOD. Hospital ( Site 2111)
Pliuty Kyiv, 08720, Ukraine
Kyiv City Clinical Oncology Center ( Site 2100)
Kyiv , 03115, Ukraine
Royal Infirmary Aberdeen ( Site 2403)
Aberdeen Aberdeen City, AB25 , United Kingdom More Info
Study Coordinator
Contact
03454566000
Ninewells Hospital and Medical School ( Site 2401)
Dundee Dundee City, DD1 9, United Kingdom More Info
Study Coordinator
Contact
01382 435543
Taunton and Somerset Hospital ( Site 2404)
Taunton England, TA1 5, United Kingdom More Info
Study Coordinator
Contact
01823333444
Barts Health NHS Trust ( Site 2409)
London London, City Of, EC1A , United Kingdom More Info
Study Coordinator
Contact
+447779785642
Guy s & St Thomas NHS Foundation Trust ( Site 2408)
London London, City Of, SE1 9, United Kingdom More Info
Study Coordinator
Contact
+442071887188
The Christie NHS Foundation Trust ( Site 2405)
Manchester , M20 4, United Kingdom More Info
Study Coordinator
Contact
0161 446 3745

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

672

Study ID:

NCT04624204

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.